Eir Ventures
SwedenKey facts
Recent exits
No exits recorded yet.
Coverage notes
0 funds tracked, 0 portfolio companies (0 active · 0 realized). Verified weekly from public filings and deal announcements.
About Eir Ventures
Eir Ventures is a dedicated Nordic life sciences venture capital firm with approximately €122 million of assets under management as of December 2024 (Eir Ventures I final close December 2021 at €122.3 million), headquartered in Stockholm with a second office in Copenhagen. The firm was founded in 2020 by founding partners Stephan Christgau and Magnus Persson and operates as a partner-owned independent firm backed by EIF, Novo Holdings, Saminvest, Vaekstfonden, Nordic universities and family offices.
Investment thesis
Eir Ventures deploys capital through one active fund (Eir Ventures I, with approximately 12-20 portfolio investments), targeting early-stage and selectively later-stage life sciences venture capital with active ownership including board seats and company creation. The investment triad emphasises transformative potential, execution excellence and scalability. Sector focus spans biotech and therapeutics, innovative medicine, drug delivery, rare diseases, healthtech and diagnostics. Geographic deployment is anchored in the Nordics (Sweden, Denmark, Finland, Norway) with a global syndication network spanning Europe and the US, sourcing from leading regional universities and incubators.
Recent activity
Recent realised exits include biotech and pharma IPO (2024). Recent acquisitions include drug delivery and pharma (2024), with no new platform investments publicly recorded in 2025-2026 as the firm focuses on portfolio support. The platform continues active deployment across the Nordic life sciences mandate. Detailed buyer names and multiple data available on Pro at €49/month.
Similar firms
Other private equity firms tracked on GP Intel.
See the full fund history.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in